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Acute effect of CyA A (Neoral) on large artery hemodynamics
in renal transplant patients.
Background. CyA A (CyA) may induce intrarenal vasocon-
striction, endothelial dysfunction, and hypertension. There are
only two contradictory reports describing the acute effect of
CyA on renal resistances measured by color Doppler flowmetry.
Therefore, we studied the acute influence of oral CyA on arte-
rial haemodynamics by assessing simultaneous changes in blood
pressure, applanation tonometry–derived pulse wave analysis
and duplex ultrasound–derived intrarenal resistance indices.
Methods. Augmentation index (AIx) (difference between the
first and second systolic peak on the aortic pressure waveform
divided by the pulse pressure = AIx) was determined from
contour analysis of arterial waveforms recorded by applana-
tion tonometry using the AtCor device in 18 live-related renal
transplants (11 females/7 males, age = 32.0 ± 8.1 years, trans-
plantation duration = 17.5 ± 16.1 months, and mean serum
creatinine = 133 ± 70 lmol/L). All studies were performed
just before (C0), and 2 hours after (C2) the oral administa-
tion of CyA. At the same C0 and C2 moments the resistive
index (RI) = (peak systolic frequency shift − minimum di-
astolic frequency shift)/peak systolic frequency shift, and pul-
satility index (PI) = (peak systolic frequency shift − minimum
diastolic frequency shift)/mean frequency shift were calculated
from Doppler recorded waveforms.
Results. Blood pressure and heart rate did not differ signifi-
cantly at C0 and at C2 serum levels: 134.3/82.9 vs. 128.1/80.0 mm
Hg and 72.0 vs. 71.0 beats/min, respectively, despite a marked
increase in whole blood concentration (CyAC0 = 90.8 ± 45.9
vs. CyAC2 = 547.4 ± 251.3 ng/mL) (P = 0.05). Mean AIx fell
significantly from 17.2 ± 13.8 to 12.9 ± 14.2 (P < 0.0001). There
was no correlation between the extent (expressed as absolute
or relative change) of the measured alteration in AIx and total
administered CyA dose, or increment in blood level between
C0 and C2. In support, the intake of CyA did not induce a
significant increase in Doppler resistance (RIC0 = 0.68 ± 0.08
vs. RIC2 = 0.70 ± 0.09) and pulsatility indices (PIC0 = 1.32 ±
0.31 vs. PIC2 = 1.33 ± 0.28). Finally, three patients were studied
twice (>1 week): one under two levels of creatinine, one with
no antihypertensives, and a third receiving verapamil initially.
All these maintained a significant decrease in AIx at C2 from
C0 supporting the reproducibility of the phenomenon.
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Conclusion. We demonstrate that Neoral CyA acutely im-
proves large arterial compliance function and does not induce
an acute rise in intrarenal resistance in stable renal transplant
subjects with normal renal function. We speculate that there
may be an effect of vitamin E, the diluent vehicle in which CyA
is carried (1000 IU/100 mg CyA), shown to improve endothelial
function.
CyA A (CyA), an inhibitor of calcineurin which sup-
presses T-cell function in vivo, has been a major part of the
immunosuppressive armamentarium for solid-organ and
bone marrow transplantation for the last two decades. Af-
ter oral administration there is rapid absorption and the
blood level of CyA reaches a peak at around 2 hours post-
oral administration. This blood level (C2 level) is thought
to mirror more closely CyA biologic activity and toxicity
than trough levels (C0 level), since it has been demon-
strated to be the best single-point predictor of area under
the concentration time curve [1] and therefore to closely
correlate with clinical outcome in the early posttransplant
period and to predict rejection risk [2, 3].
A number of undesirable side-effects have emerged
with the continued use of calcineurin inhibitors, in-
cluding dyslipidemia, glucose intolerance, increased ox-
idative stress, endothelial dysfunction, left ventricular
hypertrophy, and hypertension [4]. The etiology of the hy-
pertension is both complex and poorly understood, but
seems to involve besides fluid retention, stimulation of
the sympathetic nervous and renin-angiotensin system,
and inhibition of the action of nitric oxide, leading to
intrarenal and systemic vasoconstriction of the muscu-
lar arterioles and elevated systemic vascular resistance.
Specifically at renal level CyA induces constriction of the
afferent arteriole which results in an acute decrease in re-
nal plasma flow as shown by techniques using inulin and
aminohippuric acid [5]. More recently, duplex Doppler
ultrasound can directly measure intrarenal blood flow ve-
locity during systolic and diastolic perfusion. However,
there are only two contradictory reports [6, 7] describ-
ing acute CyA-induced vasomotoric changes as reflected
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Fig. 1. Augmentation index as a marker of arterial stiffness. Typical
pulse waveforms from normal (top) and stiffened (bottom) conduit
arteries derived from percutaneous tonometry tracings. Abbreviations
are: S, systole; D, diastole; BP, blood pressure in mm Hg; T0, time of
start; TF, time of finish of the cardiac cycle; T1, time to outgoing pressure
peak; and T2, time to peak of reflected wave; augmentation index, the
augmentation divided by the pulse pressure × 100. The timing of the
reflected wave was calculated as T2-T1.
by changes in renal resistance indices measured by color
Doppler flowmetry.
Increased peripheral resistance alters the intensity and
timing of pulse wave reflections. Therefore, the energy
of the reflected wave will combine at an earlier time-
point with the antegrade pulse wave, thus increasing the
augmentation index (AIx) (see Fig. 1). AIx is a com-
posite parameter influenced by the reflective properties
of the arterial system, and strongly dependent on pulse
wave velocity (a parameter that reflects conduit artery
compliance) and the traveling distance of pressure waves
(body height). Most important, it has been convincingly
demonstrated that the AIx derived from pulse wave con-
tour analysis is an important negative prognostic risk fac-
tor [8] in renal dialysis patients. The risk ratio for each
10% increase in AIx, after adjustment for all confounding
factors, is 1.51 (95% CI = 1.23 to 1.86) for all-cause mor-
tality and 1.48 (95% CI = 1.16 to 1.90) for cardiovascu-
lar mortality. This is relevant since at similar effects on
blood pressure, pulse pressure, and pulse wave velocity
some anithypertensives have a more favorable impact on
AIx [9]. Finally, it has been prospectively demonstrated,
in subjects longitudinally studied prior to and after live-
related transplantation, that AIx is markedly improved
after successful renal transplantation [10].
Table 1. Demographic data
Number
Patients 18
Studies 21
Gender (F/M) 11/7
Age years 32.0 ± 8.1
Height cm 176 ± 9
Transplantation duration months 17.5 ± 16.1
Time on dialysis prior to transplantation months 25 ± 15
Diabetics 1
Smokers 2
Creatinine lmol/L 133 ± 70
Hemoglobin g/dL 12.5 ± 1.9
Cyclosporine A dose mg/kg 2.30 ± 0.97
To better understand the acute effect of CyA on large
artery function (compliance and wave reflection) and its
real consequences on intrarenal hemodynamics, we stud-
ied, in stable renal transplant recipients, simultaneous
changes in blood pressure, applanation tonometry–
derived pulse wave analysis and duplex ultrasound–
derived intrarenal resistance indices, following regular
oral intake of Neoral.
METHODS
After institutional ethical approval and informed con-
sent, 18 successfully engrafted renal transplant patients
(all recipients of living donated organs) were studied. On
the day of the vascular studies patients were in good
health and had refrained from caffeine and cigarettes
(only two were chronic smokers) overnight. Table 1 gives
the patient demographics and baseline variables. All pa-
tients were also receiving 2 g of mycophenolate mofetil
(MMF) and 5 mg prednisone as part of their immunosup-
pressive regimen. Antihypertensive therapy was in use
for the majority of patients [calcium channel blockers in
15, angiotensin-converting enzyme (ACE) inhibitors in
13, beta blockers in 11, other agents in five, and no treat-
ment in three cases].
Pulse wave analysis (PWA)
All studies were performed at 8:00 a.m. and 10:00 a.m.
Measurements were taken in duplicate and averaged. The
first PWA measurement took place at least 12 hours af-
ter the last dose of CyA had been consumed, after which
blood was drawn to determine the C0 CyA level. The pa-
tient was then supervised taking the requisite oral dose of
CyA, and 115 to 125 minutes later the patient underwent
an identical PWA measurement, and blood was drawn for
C2 CyA levels. Long-acting, once-daily antihypertensives
(including calcium channel blockers) were administered
at 16:00 hours, corresponding to C12 in order to minimize
any influences from the medication.
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Radial arterial waveforms (40 cardiac cycles) were
recorded by applanation tonometry (Millar arterial pres-
sure tonometer, SphygmoCorTM) (PWV Inc., Westmead,
Sydney, Australia). Blood pressure was also measured at
the right or left brachial artery by sphygmomanometry
(mean of three readings taken after 10 minutes semire-
cumbency). An averaged composite radial waveform was
calculated from which specially designed software (PWV
Inc.) derived an aortic blood pressure waveform, in real
time, using a validated transfer function algorithm. From
the derived aortic blood pressure waveform, the follow-
ing parameters were calculated and used: T1 = time to
outgoing pressure peak, T2 = time to peak of reflected
wave, the timing of the reflected wave = T2 − T1, and
the AIx = the augmentation divided by the pulse pres-
sure × 100) (see Fig. 1 for a pictorial explanation). This
methodologic approach has been successfully used be-
fore in renal transplant patients [10, 11]. All AIx were
corrected for a standard heart rate of 75 beats per minute
(bpm) [12, 13], referred to as AIx-75.
The intraobserver error for AIx was first determined in
ten young healthy volunteers = 1.3%. The intraobserver
error for AIx was also determined in ten renal transplant
patients (1.4%, prior to the study).
Color Doppler examinations were performed in the
supine position with a Kretz SA-9900 ultrasound machine
(Kretztechnik AG, Zipf, Austria), using a multifrequency
curved array transducer (2 to 4 MHz). Intrarenal Doppler
resistance indices were measured at the same C0 and C2
moments (see above), using the same technique as [11].
The resistive index (RI) was defined as the RI = (peak
systolic frequency shift − minimum diastolic frequency
shift)/peak systolic frequency shift and the pulsatility in-
dex (PI) = (peak systolic frequency shift − minimum di-
astolic frequency shift)/mean frequency shift.
Statistical analysis was performed using SPSS 7.5 soft-
ware. Significance of differences in CyA levels, blood
pressure, heart rate, and AIx, and renal Doppler resis-
tance indices between the C0 and C2 moments was cal-
culated using the Wilcoxon signed rank test and paired t
tests as appropriate. The level of significance was consid-
ered P < 0.05.
RESULTS
Twenty-one paired C0 and C2 PWA measurements
took place in 18 patients (see Table 1). Mean AIx fell
significantly from 17.2 ± 13.8 to 12.9 ± 14.2 (P < 0.0001).
Fourteen of such paired measurements revealed a de-
crease in central AIx comparing the C0 moment with the
C2 moment. Two measurement pairs showed no alter-
ation in AIx, and five showed a modest increase in AIx
after CyA. These findings are shown diagrammatically
as Figure 2 and summarized in Table 2. There was no
correlation between the extent (expressed as absolute or
Table 2. Moment of cyclosporine A oral administration (C0) vs. 2
hours (C2) after administration: A comparison between
hemodynamic parameters
C0 moment C2 moment P value
Systolic blood pressure 134.3 ± 27.1 128.1 ± 24.9 NS
mm Hg
Diastolic blood pressure 82.9 ± 13.1 80.0 ± 15.5 NS
mm Hg
Central mean blood pressure 101.1 ± 18.1 95.6 ± 18.5 NS
mm Hg
Heart rate beats/min 72.0 ± 13.8 71.0 ± 14.8 NS
Cyclosporine A level ng/mL 90.8 ± 45.9 547.4 ± 251.3 <0.00001
Augmentation index % 17.2 ± 13.8 12.9 ± 14.2 <0.0001
T2-T1 mseconds 107.1 ± 29.5 97.3 ± 18.8 0.05
Resistive index 0.68 ± 0.08 0.70 ± 0.09 NS
Pulsatility index 1.32 ± 0.31 1.33 ± 0.28 NS
T1 is time to outgoing pressure peak; T2 is time to peak of reflected wave (see
Fig. 1); T2-T1 is timing of the reflected wave; resistive index (RI) = (peak systolic
frequency shift − minimum diastolic frequency shift)/peak systolic frequency
shift; pulsatility index (PI) = (peak systolic frequency shift − minimum diastolic
frequency shift)/mean frequency shift.
relative change) of the measured change in AIx and total
administered CyA dose, or increment in CyA blood level
between C0 and C2. Furthermore, there were no signif-
icant differences between patients in which a fall in AIx
was recorded and all the other patients in which AIxC2
increased or was similar to AIxC0. Specifically, there was
no difference in antihyprtensive medication use, calcium
channel blockers, or statins.
To test the reproducibility of our observations under
different conditions, three patients were studied twice:
patient 1, patient 3, and patient 4 (Fig. 2). The second set
of recordings was at > 1 week after the first, as follows:
patient 1 was studied under different levels of creatinine
(1.3 and 2.5 mg/dL, respectively). Patient 3 had on the
two occasions the (1) same level of creatinine and (2) no
antihypertensives. Patient 4 was on 240 mg verapamil for
the first experiment and without medication for the sec-
ond experiment. In all these three patients studied twice
there was a decrease in AIx on each occasion. Further-
more, five patients were studied at +2 hours (C2), +6
hours (C6), and +14 hours (C12) after the initial C0 (see
Fig. 3). C6 and C12 AIx values were almost identical to
C0 AIx levels. Finally, we performed two measurement
2 hours apart in ten matched (age, gender, and blood
pressure levels) essential hypertensive patients with nor-
mal renal function. All patients were on amlodipine and
three were also taking indapamide. All measurements
were performed at 2 hours after the ingestion of the anti-
hypertensive medication. Mean AIx was extremely sim-
ilar on the two occasions (15.2 ± 9.8 to 14.9 ± 8.7) (P =
NS).
Since AIx is a composite parameter influenced by arte-
rial stiffness and peripheral arterial reflective properties
we further dissected the influence of CyA on arterial wall
properties by calculating the timing of the reflected wave
at baseline and 2 hours after Neoral administration.
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Fig. 2. Change in augmentation index (AIx)
from moment of cyclosporine A (CyA) ad-
ministration (C0) to 2 hours after administra-
tion (C2). The change corresponds to trough
and + 2 hours CyA levels, respectively, for 18
patients. For each patient the two-paired AIx
values are presented. Baseline AIx (at C0) is
depicted in black while AIx at C2 is depicted
in gray. Three patients (1, 3, and 4) were stud-
ied twice, the second set of recordings was at
> 1 week after the first.
Compared to the baseline values 13 patients had a de-
crease in the timing of the reflected wave (Fig. 4) at the
C2. Overall values are presented in Table 2.
The intake of CyA did not induce a significant increase
in Doppler resistance indices: RIC0 = 0.68 ± 0.08 vs. RIC2
= 0.70 ± 0.09; and pulsatility indices: PIC0 = 1.32 ± 0.31
vs. PIC2 = 1.33 ± 0.28 (P = NS). Again, there was no
correlation between the extent (expressed as absolute or
relative change) of the measured alteration in RI or PI
and total administered CyA dose, or increment in blood
level between C0 and C2.
DISCUSSION
This study examines for the first time the acute effect
on large artery compliance function of the administration
of oral CyA in renal transplant recipients with good renal
function. The findings suggest an improvement in the aor-
tic AIx despite a decrease in the timing of the reflected
wave, following Neoral administration. Acute changes
in AIx measured by the PWA technique may reflect sig-
nificant changes in large arterial compliance function or,
alternatively, a reduction in wave reflections from periph-
eral sites. However, the present constellation of findings,
including similar renal Doppler resistance indices at C2,
decreased timing of the reflected wave, and significantly
decreased AIx, suggests that, at least in some patients,
CyA acutely induces an improvement in large artery com-
pliance. This effect was not detectable simply by measur-
ing brachial arterial blood pressure values or from the
derived measurements of central aortic blood pressure
values using the analytical software.
There is only one report in the literature of the effect of
renal transplantation per se on large artery compliance
function showing prospectively a marked improvement
3 months after successful engraftment [10]. Although all
the patients in that study were taking CyA there are
numerous additional different drug and patient factors
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Fig. 3. Serial changes in augmentation index (AIx) during a 24-hour
period, in relation with cyclosporine A (CyA) administration. Abbre-
viations are: C0, moment of administration; C2, 2 hours after adminis-
tration; C6, 6 hours after administration; C12, 12 hours after adminis-
tration.
that may be relevant to cardiovascular changes taking
place pre- to postrenal transplantation. In another cross-
sectional analysis, including 250 patients similarly studied
[11], it was found on multivariate analysis that gender,
age, height, heart rate, mean arterial pressure, total time
on renal replacement therapy, and use of CyA were the
only relevant correlates for AIx, accounting for 60% of
the recorded variance. Diabetes, hemoglobin, albumin
and cholesterol levels, creatinine clearance, smoking his-
tory, and use of antihypertensive or lipid-lowering medi-
cation were not found to be significant determinants. De-
mographic determinants of AIx were not relevant in our
study since the two sets of measurements were performed
in the same patients, while blood pressure and heart rate
were similar between the two moments. Most important,
our baseline AIx, as a crude marker of arterial compli-
ance, is in line with values reported by Ferro et al [11],
taking into account the important difference in age and
transplant duration between the two study populations.
At first sight, this finding of improved large arterial
compliance function seems counterintuitive in the con-
text of the known pressor effects of chronic CyA ad-
ministration and of previous data on renal plasma flow
following CyA administration [5]. However in a very re-
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Fig. 4. Changes in the timing of the reflected wave at baseline and
2 hours after Neoral administration. Abbreviations are: T1, time to
outgoing pressure peak; T2, time to peak of reflected wave (see also
Fig. 1). The timing of the reflected wave was calculated as T2 − T1.
cent report Heine et al [7] demonstrated by duplex ul-
trasound examinations that oral intake of CyA does not
induce an acute rise in intrarenal Doppler resistance in-
dices in stable renal transplant patients, similar to our own
Doppler findings. This significant difference from an ear-
lier Doppler study was attributed by Heine et al [7] to dif-
ferences in CyA formulation (Neoral vs Sandimmune)
and to a lower dose (i.e., 2.3 ± 0.1 mg/kgc/day (identical
to ours) vs. 4.5 ± 0.5 mg/kgc/day). It is also possible that
because of the small patient numbers an effect of CyA on
renal Doppler resistance indices could have been missed
(type II error).
An alternative explanation of our findings might be
provided by an independent vasoactive effect of the dilu-
ent vehicle in which the CyA is carried (as Neoral cap-
sules). Each capsule of Neoral CyA contains a large con-
centration of vitamin E (1000 IU/100 mg CyA). Thus, pa-
tients were administered anything from 1500 IU to 5000
IU vitamin E in the form of Neoral CyA. Vitamin E
is known as an antioxidant free-radical scavenger, and
has been shown to improve small and large vessel, and
endothelial, function in short-term oral administration
to diabetic subjects [14]. Administration of intravenous
CyA (free from vitamin E), and separately, oral vitamin
E at a similar concentration to that seen in the context of
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oral Neoral CyA administration, would allow this hy-
pothesis to be tested directly.
As previously stated it has been shown in a large cross-
sectional study that transplant patients chronically ex-
posed to CyA had increased aortic AIx (stiffer aorta,
reduced compliance) compared to a subset of patients
exposed to tacrolimus [11]. It is also clear that elective
removal of CyA from the immunosuppressive regimen
leads not only to long-term improvement in renal func-
tion but to a marked fall in brachial blood pressure [15].
Thus a prospective study of aortic compliance function
after renal transplantation with the intended removal of
calcineurin inhibitors would allow a deeper understand-
ing of their complex cardiovascular consequences.
CONCLUSION
We demonstrate that Neoral CyA acutely improves
large arterial compliance function and does not induce
an acute rise in intrarenal resistance in stable renal trans-
plant subjects with normal renal function. Further stud-
ied are required to elucidate these provocative findings,
including a possible role for vitamin E on endothelial
function.
Reprints requests to Adrian Covic, M.D., Ph.D., Parhon University
Hospital, 50 Carol 1st Blvd., Iasi 6600, Romania.
E-mail: acovic@xnet.ro
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